City Therapeutics IPO Raises $200M for RNAi Drugs Beyond the Liver
City Therapeutics raised $200 million in an upsized IPO to advance RNAi therapies for clotting, eye disease, and anemia beyond liver targets.
This section contains the website’s posts.